CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS

Having the Courage of Our Convictions

1-2 October 2015 • Paris

Things We Know: What Advances in HIV Treatment Mean in the Context of Ending AIDS?

Benjamin Young, MD PhD International Association of Providers of AIDS Care



Things we know

- Treatment works
- Treatments are better
- Scale up is feasible and it's happening
- Price of inaction
- Path forward

Treatment Works

The NEW ENGLAND JOURNAL of MEDICINE


ESTABLISHED IN 1812

AUGUST 27, 2015

VOL. 373 NO. 9

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

The INSIGHT START Study Group*



CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

INSIGHT START study group, NEJM 2015

Subgroup	Percentage in Group		Deferred Initiation its with event 00 person-yr)	Hazard Ratio (95%	CI)	P Value for Interaction
Age						0.98
≤35 yr	48.8	15 (0.43)	31 (0.91)		0.47	
>35 yr	51.2	27 (0.78)	65 (1.85)	_	0.42	
Sex				: 1		0.38
Male	73.2	35 (0.66)	74 (1.40)	_ _	0.47	
Female	26.8	7 (0.42)	22 (1.34)	• ¦	0.31	
Race				:		0.65
Black	30.1	15 (0.82)	28 (1.52)		0.57	
White	44.5	21 (0.63)	53 (1.54)	•¦	0.40	
Other	25.4	6 (0.34)	15 (0.91)		0.37	
Geographic region						0.55
High income	46.0	20 (0.56)	51 (1.42)	•¦	0.39	
Low or moderate income	54.0	22 (0.65)	45 (1.35)	<u>.</u>	0.48	
Baseline CD4+						0.71
<600 cells/mm ³	31.5	10 (0.44)	35 (1.54)		0.28	
600-800 cells/mm3	48.6	24 (0.70)	46 (1.38)	<u>_</u> !•	0.50	
>800 cells/mm ³	19.9	8 (0.63)	15 (1.14)		- 0.56	
Baseline HIV RNA						0.25
<5000 copies/ml	31.8	12 (0.56)	18 (0.83)		- 0.66	
5000-30,000 copies/ml	35.5	13 (0.53)	36 (1.41)	•i	0.38	
>30,000 copies/ml	32.5	17 (0.72)	42 (1.92)	•;	0.37	
Smoker				1		0.93
Yes	31.9	18 (0.78)	43 (1.81)		0.43	
No	68.1	24 (0.52)	53 (1.16)	_	0.44	
Framingham 10-yr CHD risk						0.56
<0.8	32.7	8 (0.35)	17 (0.77)	_	0.46	
0.8-3.6	32.3	11 (0.48)	27 (1.23)	•;	0.39	
>3.6	33.5	23 (1.00)	50 (2.05)		0.50	
				0.25 0.50 1.00	2.00	
				Immediate Initiation Defe Better	erred Initiation Better	

CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions


INSIGHT START study group, NEJM 2015

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa

The TEMPRANO ANRS 12136 Study Group*



Treatment is Prevention

Treatment is Prevention

HPTN 052 - Conclusions

- The benefit of early ART in HIV prevention among HIV-discordant couples is durable
- No index-to-partner (linked) HIV transmissions were observed when the index participant was stably suppressed
- ART is highly effective for prevention of sexual transmission of HIV

CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

MS Cohen, IAS2015

Treatment is Prevention



Conclusions

No index-to-partner transmission events were observed when the index was stably suppressed on ART

In the setting of TasP, special efforts should be made to minimize HIV transmission risk before the index is virally suppressed, to achieve durable viral suppression on ART, and to identify and address ART failure


CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

S Eshleman, IAS2015

PEP Works

Notes from the Field: Occupationally Acquired HIV Infection Among Health Care Workers -United States, 1985-2013

Weekly January 9, 2015 / 63(53);1245-1246



PrEP Works

Clinical Infectious Diseases Advance Access published September 24, 2015

BRIEF REPORT HIV/AIDS


No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting

Jonathan E. Volk,¹ Julia L. Marcus,² Tony Phengrasamy,¹ Derek Blechinger,¹ Dong Phuong Nguyen,¹ Stephen Follansbee,¹ and C. Bradley Hare¹

¹Department of Adult and Family Medicine, Kaiser Permanente San Francisco Medical Center, and ²Division of Research, Kaiser Permanente Northern California, Oakland, California

Referrals for and initiation of preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection increased dramatically in a large clinical practice setting since 2012. Despite high rates of sexually transmitted infections among PrEP users and reported decreases in condom use in a subset, there were no new HIV infections in this population.

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial



CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions


S McCormack, Lancet 2015

Near elimination of HIV transmission in a demonstration project of PrEP and ART

HIV incidence

 The observed incidence is a 96% reduction compared to expected, a result that was highly statistically significant

HI



CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

Baeten, CROI2015

Treatments are getting better

First-line integrase inhibitors VS 3rd agents

Drug	vs. EFV	vs. PI/r
Raltegravir	Superior*	Superior
Elvitegravir/c obicistat	Non-inferior Non-inferior (switch)	Superior (women) Superior (switch)
Dolutegravir	Superior	Superior



Dolutegravir vs Efavirez

Week 144 Treatment-emergent Resistance

		DTG + ABC/3TC QD (N=414)	EFV/TDF/FTC QD (N=419)
Subjects with PDVF		39 (9%)	33 (8%)
Primary INI-r		0	0
Primary NRTI	K65R	0	1
Primary NNRTI	Any	0	6
	K101E	0	1
	K103N	0	2
	K103K/N	0	2
	G190G/A	0	2

PDVF definition:

- Confirmed HIV-1 RNA ≥50 c/mL at or after Week 24
- PDVF triggered resistance testing for all subjects
- PDVF before week 48 required withdrawal from study
- After week 48, subjects with HIV RNA 50-200 c/mL could remain on study

PDVF: protocol defined virologic failure

CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

Walmsley, N Engl J Med, 2011; Pappa, 54th ICAAC 2014

Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States

Table 6. Differences in Median Total All-Cause Health Care Costs among Matched Event Episodes.

AE	Episodes with Event of Interest	Episodes without Event of Interest	Difference	P Value ^a
Depression	US\$677	US\$0	US\$677	<.0001
Diabetes/insulin ^b resistance	US\$14 547	US\$11 237	US\$3310	.0021
Diarrhea	US\$560	US\$0	US\$560	<.0001
Dizziness	US\$521	US\$0	US\$521	<.0001
Hepatic disorders	US\$212	US\$0	US\$212	.0005
Lipid disorders ^b	US\$12 825	US\$10 033	US\$2792	.0004
Nausea/vomiting	US\$772	US\$0	US\$772	<.0001
Rash	US\$390	US\$0	US\$390	<.0001
Renal disorders	US\$1389	US\$0	US\$1389	<.0001
Somnolence/sleep effects	US\$357	US\$0	US\$357	<.0001

Abbreviation: AE, adevrse event.


^aWilcoxon signed-rank test was used to compare differences in median total all-cause health care costs.

^bHandled as chronic events, whereby patients can have only 1 "episode".



Dekoven, et al., JIAPAC, 2015

Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States





CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

Dekoven, et al., JIAPAC, 2015

It's Beginning to Work

Addressing the Achilles' Heel in the HIV Care Continuum for the Success of a Test-and-Treat Strategy to Achieve an AIDS-Free Generation





CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

J Nachega, Clin Infect Dis 2014

US Cities

- San Francisco¹:
 - 94% tested
 - 84-91% on ART
 - 64% viral suppressed
 - Denver²:
 - 90% tested
 - 68% on ART
 - 57% viral suppressed


CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

¹RM Grant, CROI2015 ²Denver Health 2015

OPEN O ACCESS Freely available online

PLOS ONE


Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada



CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

Samji, PLOS One 2013


Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies



CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

LF Johnson, PLOS Medicine 2013

Life expectancy




Concerns

Concerns about ART scale up


- Stigma
- Coercion, loss of individual rights
- Risk compensation
- Adherence
- ART resistance
- Political theatre, not action

Journal of Antimicrobial Chemotherapy

Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999–2011




TDR Prevalence by Class per Year



CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

Walworth, ICAAC 2015, LB3389

HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study




CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

The Lancet Infectious Diseases 2011 11, 750-759DOI: (10.1016/S1473-3099(11)70149-9)

Price of Inaction




Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990– 2013



CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

Granich, PLOS One 2015



- 47 days since publication of START
 - 4100 AIDS-related deaths per day
 - 193,000 preventable deaths

Making it Happen

IAPAC GUIDELINES FOR OPTIMIZING THE HIV CARE CONTINUUM FOR ADULTS AND ADOLESCENTS

- Optimizing the care environment
- Increasing HIV testing coverage and linkage to care
- Increasing HIV treatment coverage
 - The immediate offer of ART after HIV diagnosis, irrespective of CD4 count or clinical stage, is recommended
 - Viral load testing at least every six months is recommended as the preferred tool for monitoring ART response
- Increasing retention in care, ART adherence and viral suppression
- Metrics for monitoring the HIV care continuum

CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Having the Courage of Our Convictions

LG Bekker, IAS 2015; International Advisory Panel on HIV Care Continuum Optimization, JIAPAC, in press



GUIDELINES

GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV

SEPTEMBER 2015

- ART should be initiated in all adults living with HIV at any CD4 cell count
- Oral PrEP should be offered as an additional prevention choice for people at substantial risk of HIV infection

DHHS 28 Jul 2015:


ART is recommended for HIV-infected patients regardless of pretreatment CD4 count level (A1)

WHO: 30 Sep 2015

Recommendation 1: When to start ART among people living with HIV			
Target population	Specific recommendation	Strength of the recommendation	Quality of the evidence
Adults* (>19 years)	ART should be initiated in all adults living with HIV at any CD4 cell count	Strong	Moderate NEW
	As a priority, ART should be initiated in all adults with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and individuals with CD4 count ≤350 cells/mm ³	Strong	Moderate




HIVpolicywatch.org






HIVpolicywatch.org



Current Fast-Track Cities

	AFRICA	LATIN AMERICA/CARIBBEAN
1. Abidjan	16. Durban	30. Buenos Aires
2. Accra	17. Kinshasa	31. Curitiba
3. Algiers	18. Lagos	32. Kingston
4. Atakpamé	19. Libreville	33. Port-au-Prince
5. Bamako	20. Lilongwe	34. Salvador de Bahia
6. Bamenda	21. Lomé	35. Santa Fe
7. Bangui	22. Lubumbashi	36. Santiago
8. Blantyre	23. Lusaka	37. San Miguelito
9. Casablanca	24. Maputo	Ŭ
10. Cotonou	25. Mbujimayi	
11. Dakar	26. Nairobi	
12. Dar es Salaam	27. Ouesso	
 13. Djibouti 14. Djougou 	28. Windhoek	
14. Djougou 15. Douala	29. Yaounde	
13. Douald		
EUROPE	ASIA	NORTH AMERICA
38. Amsterdam	43. Bangkok	46. Atlanta
39. Brussels	44. Delhi	47. Denver
40. Bucharest	45. Mumbai	48. Miami
41. Geneva		49. San Francisco
42. Paris		
		MIC WITH ANTIRETROVIR


IAPAC African Regional Capacity Building Hub



- Mission to strengthen clinician capacity on HIV, HBV and HCV clinical management.
- Help to integrate and implement WHO and other normative guidance

"We scientists don't communicate well"

- To communicate to public more efficiently:
 - There is clear consensus
 - Impact is already happening
 - The risks are acceptable because the consequences are serious
 - We can do something about this at a reasonable cost



Mario Molina, PhD Nobel Prize, 1995

What must be done?

- Guidelines and proclamations must not just be signatures on paper
- Support bold leadership and targets with action
- Demand non-judgmental testing, care and treatment must match the magnitude of preventable death
- We must not forget the need to support cadres of well-trained care providers
- We must not forget that every data point is a human being

Things we know

- HIV treatments work.
 - Prevent disease, death and transmission
- Treatments are even getting better
- The risks of not acting outweigh the risks of implementing
- ART impact is already happening
- Thousands are at risk every day. We must have the courage to act now.